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Translocation of the c-myc protooncogene into or near one of the Ig loci is
found in almost every case of Burkitt's B cell lymphoma in man and experimen-
tally induced plasma cell tumor in the mouse (reviewed in references 1, 2). This
accidental rearrangement ofthe cellular genome appears to free the c-myc gene
fromitsnormal susceptibility to negativeregulation and to render it constitutively
active in cells that express Ig genes (reviewed in references 1-4). The contribu-
tion of the rearranged gene to the neoplastic phenotype may stem from the
abilityofthemycpolypeptide todrive cellularproliferation, perhaps bypromoting
DNA replication (5, 6). While its biochemical function is not yet defined, c-myc
expression normally correlates closely with cell-cycle activity in a broad range of
cell types, increasing greatly when resting cells are mitogenically stimulated and
declining when they cease to proliferate (3, 4, 7).
The effects of altered oncogenes on cells in their natural environment can be
assessed through the use oftransgenic mice (8, 9). A transgenic strain is initiated
by inserting a gene into the mouse genome and is perpetuated thereafter by
normal breeding. By this means, a c-myc gene coupled to regulatory sequences
from the mousemammary tumor virus was shown to causemammary carcinomas,
and sometimes other tumors, after a substantial latent period (10, 11). To mimic
the translocated myc genes found in lymphoid tumors, we introduced into mice
a DNA sequence, designated EA-myc, isolated from a mouse plasmacytoma in
which a normal myc gene had become coupled to the Ig heavy chain enhancer
(12). In the resultant transgenic mice, the El-myc transgene appears to be
expressed exclusively in B-lymphoid cells (13) and causes them to proliferate
more than normal (14). Starting before birth, the pre-B cell population expands
progressively up to about five times its normal size, while B cells are somewhat
reduced in number despite their increased cell-cycle activity (14). The immune
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LYMPHOMA AND LEUKEMIA IN E/-myc MICE
responsiveness of Ej-myc animals is not greatly affected by these perturbations
(15) . Thus, the excessive proliferative activity induced by the EA-myc gene is
limited and benign. However, these mice also develop lymphomas of B-lineage
cells (16).
To establish the Eg-myc mouse as a model of lymphomagenesis, we here
quantify the incidence, pathology, and cell surface phenotypes of the tumors.
Despite some variation in the pathology, all of the tumors have proven to be
malignant lymphomas of B-lineage cells, usually accompanied by lymphoid leu-
kemia. We compare them with other mouse lymphomas and with the tumors
that characterize the SJL strain, a contributor to the genetic background of the
transgenic line. We also describe a characteristic of the blood of young EA-myc
mice that provides a rapid means of distinguishing them from normal mice.
A notable feature of these mice is that lymphomagenesis has proven to be
virtually inevitable. Nevertheless, individual tumors appear to initiate at random
with age. Analysis of the kinetics of tumor onset allows us to estimate the rate of
malignant conversion within the susceptible cell population.
Materials and Methods
Mice.
￿
Primary transgenic mice and initial breeding lines were produced by the tech-
niques of Brinster et al. (17, 18) using the EA-myc DNA construct specified by Adams et
al . (16), and (C57BL/6J x SJL/J)F2 embryos descended from inbred mice purchased from
TheJackson Laboratory (Bar Harbor, ME). For subsequent detailed analysis, the Et-myc
292-1 transgenic line was propagated by breeding (heterozygous) transgenic males with
normal (C57BL/6JWehi x SJL/JWehi)F, hybrid (BSJFI)` females. As expected, -50% of
the progeny were transgenic. Transgenic females were not generally used for breeding
because of their high risk of developing lymphomas before their pups reached weaning
age. Animals used for assessing tumor onset kinetics were produced by mating multiple
BSJFI females with 4 third-generation transgenic males to randomize the contributions
of C57BL and SJL traits. At 3 wk of age, the progeny of BSJFI x transgenic matings
were segregated by gender and numbered by ear punching. To identify transgenic pups,
DNA extracted from tail tips (18) was hybridized with "P-labeled pUC12 plasmid DNA,
sequences of which were present in the introduced E,u-myc construct (16). An alternative
test using blood cell nuclei is described below. When it was necessary to retest older
animals for transgene carriage, DNA was extracted either from a skin biopsy or from the
liver after sacrifice.
The mice were maintained under clean conventional conditions with free access to 2.5
Mrad-irradiated mouse breeder ration cubes (Barastoc Stock Feeds, Victoria, Australia)
and acidified filtered tap water (3 mM HC1).
Monitoring Tumor Development.
￿
At weekly intervals after weaning, each mouse was
closely inspected and its inguinal lymph nodes were palpated to detect enlargement. Any
animal with an overt tumor was examined more frequently so that it could be autopsied
when it became ill. For histology, soft tissues were fixed in Bouin's solution, bony tissues
in neutral buffered 10% formalin . Paraffin-embedded fixed tissues were sectioned 4 Am
thick and stained with hematoxylin and eosin.
Electronic Counting of Cells and Sizing of Nuclei.
￿
The equipment comprised a Zm
Counter and C1000 Channelizer (Coulter Electronics Ltd., Luton, United Kingdom)
connected to a microcomputer. These units were interfaced and programmed by Dr. F.
Battye of the Walter and Eliza Hall Institute Flow Systems Laboratory. The system was
calibrated with 9 .7 Am polydivinylbenzene latex (Coulter Electronics Ltd.) and verified
electronically for linearity of response.
Leukocytes were counted and sized as nuclei, obtained by adding the cell lysing agent,
Zaponin (Coulter Electronics, Ltd.), to diluted blood. The diluent was PBS containing 5
mM KCI and adjusted to mouse tonicity (305-310 mosmol/kg). Blood was obtained fromHARRIS ET AL.
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TABLE I
Time Parameters of Tumor Development
134 mice from the fourth generation of the Ew-myc 292-1 line were
monitored for tumor development as described in Materials and Methods.
the retroorbital sinus using heparinized capillaries, or by cardiac puncture from animals
anesthetized intraperitoneally with tribromoethanol. For routine typing of weanling mice
for enlarged leukocyte nuclei (see Results), 5 ul of retroorbital blood was diluted into 20
ml ofdiluent and 6 drops of Zaponin were addedjust before the Coulter Counter analysis.
The particle volume range used for counting and sizing was 22-110 fl.
Cell Surface Antigen Expression.
￿
The presence of Thy-1, Ly-5(13220), and Ig antigens
on cells dispersed mechanically from tumors was detected by flow cytometric analysis of
immunofluorescence as described (14).
Results
Lymphomas in Primary Transgenic Mice and their Descendants. The EJ-myc
construct was highly tumorigenic in independent transgenic lines. Of 15 primary
transgenic mice that developed from eggs microinjected with the EU.-myc con-
struct, 12 became ill with lymphomas at 6 to 14 wk of age. Of the other 3, one
was found cannibalized at 6 wk, another died at 34 wk without gross evidence
of lymphoid pathology, while the third, which remained healthy for more than
a year, was suspected of mosaicism from the low rate (2/13) at which the
transgene was transmitted to its progeny. From five of the primary animals,
breeding lines were initiated through matings with normal BSJF1 mice. All their
transgene-bearing progeny developed lymphoid tumors, almost all becoming ill
at 6-18 wk ofage. The median onset of illness was 11 wk for the whole pool of
12 primary and 41 second- and third-generation animals. It varied only between
10 and 13 wk in the five separate lines. Consequently, one of the lines (denoted
292-1) was arbitrarily selected for long-term breeding and detailed investigation.
Tumor Onset and Progression.
￿
Tumor development was assessed in the entire
fourth generation of the Ep.-myc 292-1 line (134 animals) . In 83% ofanimals the
first sign was enlargement of one or both inguinal lymph nodes, detected by
palpation. A few mice died unexpectedly, but the others were killed for autopsy
when they became ill, as manifest by hunched posture, slow movement, ruffled
fur and, often, tachypnea.
The time course of disease varied markedly between individuals, in both the
age at which the first signs appeared and the rate of progression to illness or
death (Table I). The male and female incidence was equivalent (not shown). The
onset of first externally detectable signs and of terminal illness as functions of
age are plotted as semi-log "survival" curves in Fig. 1. The curves appear to have
three components (see Discussion). A major portion of the population (^-70%)
produced a plot closely approximating a simple exponential over the age range
from 6 to ^-16 wk, so that the frequency of appearance of new tumor cases
Pathology onset Median age 9 wk
Age range 3-81 wk
Illness or death Median age 12 wk
Age range 6-83 wk
Progression from first signs to Mean time ± SD 25 ± 19 d
illness or death Range 0-94 d356
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FIGURE 1 .
￿
Onset of tumors and appearance of
terminal illness with age in Eu-myc mice. The first
sign of lymphoma wasdesignated as "onset" and ill
health (oractual death) as "death." Regression lines
were calculated for the ranges of "onset" data
points indicated. Data from 70 females and 64
males (as in Table 1) were pooled.
TABLE 11
Autopsy Findings in Mice with Advanced Disease
Feature
Enlarged lymph nodes and spleen
Tumor (orswelling) on thoracic vertebral column
Enlarged thymus (threefold or more)
Bowel obstruction
Hind limb paralysis
Incidence
84*
68
54
13
1.5
134 EI.L-myc mice (asin Table I) were autopsied when illor afternatural
death.
* The 16% withoutgeneral enlargement of lymph nodes comprised nine
cases ofthymoma, five of intussusception, four with a single large lymph
node, and four with no grossly visible pathology.
among hitherto healthy animals (the hazard rate) was constant at 17% per
week . The "death" curve was displaced by about 3 wk and was parallel. Below 5
wk of age, the hazard rate was lower and progression slower, terminal illness
requiring an average of 5 wk to develop. Animals that remained free of disease
for more than ^-17 wk were subject to a reduced hazard rate of ^"6% per week.
Once initiated, their tumors progressed rapidly to terminal illness in 1-3 wk.
Lymphomatosis is an essentially inevitable fate for Eu-myc mice. >90% had
succumbed within 6 mo . By 1 yr only two of the original 134 animals remained
healthy. One was found cannibalized at 65 wk, and the other developed tumors
at 81 wk of age.
Gross Pathology.
￿
Dissections revealed gross evidence of disseminated lym-
phoma in all but 4 of the 134 animals. Typically, most or all lymph nodes were
enlarged 5-50-fold and the spleen 2-6-fold (Fig. 2, A and B). Enlargement was
usually similar in bilaterally paired lymph nodes. Frequencies of particular
autopsy findings are given in Table II .
A majority of animals showed substantial enlargement of the thymus, in at
least some cases clearly distinct from the three enlarged mediastinal (parathymic)
lymph nodes adjacent to it. In nine of the animals, a thymoma was the dominant
abnormal tissue mass (Fig. 2C). Another common finding in the thorax was aHARRIS ET AL .
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FIGURE 2 .
￿
Dissections of EA-myc mice with advanced tumors and of BSJF 1 mice bearing
transplanted Ek-myctumors. (A) 13-wk-oldEA-myc mouse with typical enlargement oflymphoid
organs including the Peyer's patches and the thymus (x 0.7); (B) same animal after removal
of loose abdominal and thoracic organs to reveal greatly enlarged renal and lumbar lymph
nodes and thickening of thoracic vertebral column (x 1.1) ; (C) 9-wk-old EA-myc mouse with
large thymoma but near-normal lymph nodes (X0.9) ; (D) 11-wk-old EA-myc mouse with topof
skull hinged open to show layer of tumor adhering to the parietal and interparietal bones
(x 2.2); (E) BSJF1 animal, 35 d after injection intraperitoneally and subcutaneously of 100
mesenteric lymph node cells from alymphomatous Ew-myc mouse, showinga large tumormass
at the site of injection (left), a flat subcutaneous mass on the contralateral side, and enlarged
lymph nodes, thymus and spleen (x 0.9) ; (F) BSJFI, recipient of 10' femoral bone marrow
cells from another primary tumor mouse, showing flat subcutaneous masses near the axillae,
enlarged lymphnodesand thymus,tumor tissue around the heart, and some thickening ofthe
thoracic vertebralcolumn (X 1) .
visible swelling along the vertebral column (Fig . 2B), sometimes in the form of
a discrete tumor terminating anterior to the diaphragm . In some animals, the
Peyer's patches were enlarged (Fig . 2A) . Tumor growth within the wall of the
small bowel presumably caused the bowel obstruction found in 13% of the
animals . This usually took the form of intussusception, which rapidly caused
terminal illness . About one-quarter of all the animals had tumor masses inside
the skull adherent to the parietal and interparietal bones (Fig . 2D), occasionally358 LYMPHOMA AND LEUKEMIA IN Era-myc MICE
FIGURE 3 A-F.HARRIS ET AL .
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FIGURE 3.
￿
Histologyof Eu-myt tumors . Sheets of lymphoblasts replacing the lymphocytes in
(A) the brachial lymph node (x 600) and (B) the thymus (x 600) ; (C) lymphoblasts in the
splenic white pulp (left) and lymphoblasts among nucleated erythroid and other cells in the
red pulp (right) (x 600) ; (D) liver with large deposits of lymphoblasts and lobular infiltration
(x 60) ; (E) lung with a large pleural mass and hypercellularity in the parenchyma (x 60),
revealed at higher power as F, infiltration of alveolar septa causing collapse of air spaces
(X 600) ; (G) a layer of tumor cells on the surface of the heart with limited penetration of
cardiac muscle (x 90) ; (H) transverse section of thoracic cage showing tumor on the ventral
surface and infiltrating neighboring muscle (x 14); (1) tumor mass attached to parietal bone
of the skull (x 37); (,J) Peyer's patch enlarged by lymphoblasts and intruding into the lumen
of the small bowel (x 18) ; (K) intussusception, with a lymphoblast-enlarged Peyer's patch
everted and drawn into adjacent bowel (x 9) ; (L) blood smear showing lymphoblasts and
granulocytes (x 600) .
large enough to deform the skull and depress the cerebrum and cerebellum .
The other major organs with visible abnormalities were the liver, which was
often enlarged (up to twofold) ; the lungs, which occasionally had a few presump-
tive tumor deposits ; and the skin, which sometimes showed flat masses oftumor360
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spreading posteriorly from the axillary region, presumably through mammary
tissue.
Histopathology.
￿
Histologic examination of 60 animals with advanced tumors
revealed tumor cells within many tissues. In the enlarged lymph nodes, the
normal architecture was largely obliterated. Normal cells were almost completely
replaced by medium-sized cells with little cytoplasm and open-looking, often
indented, nuclei containing large nucleoli and fine reticular chromatin, i.e.,
lymphoblasts (Fig. 3A). The thymus appeared similar (Fig. 3B), even in some of
the mice in which it was not grossly enlarged. The cortex tended to be more
densely packed with lymphoblasts than the medulla. In one case the thymus was
normal except for patches ofabnormal lymphoblasts in the cortex, presumably
representing an early stage ofthymic invasion by tumor cells.
The spleen and bone marrow were altered even in young healthy Ew-myc mice.
The pretumor spleen was up to twice normal size, and its red pulp showed
greatly increased extramedullary hematopoiesis, with many more megakaryo-
cytes and nucleated erythroid cells, albeit less erythrocytes than normal. Many
lymphoblasts were scattered through the red pulp (but were not apparent in the
white pulp). In terminally ill animals, the red pulp sometimes contained more
abundant lymphoblasts, which largely or completely replaced normal lympho-
cytes in the white pulp (Fig. 3 C). Pretumor bone marrow was dominated by pre-
B lymphoblasts (14). In the femoral marrow ofanimals withadvanced lymphoma,
there was often a further increase in the number, and sometimes the size, of
lymphoblasts, although general hematopoietic activity was never completely
displaced (not shown).
In tumorous animals, the liver was routinely invaded by lymphoblasts, which
formed variable-sized masses in portal areas, and sometimes infiltrated the liver
parenchyma, occupying the sinusoids of the lobules (Fig. 3D). While none of 8
kidneysexamined histologically showed invasion, lungsfrom 17 diseased animals
all showed widespread diffuse infiltration of the alveolar septa by lymphoblasts.
The resulting partial collapse of the alveolar air spaces (Fig. 3, E and F) may
have caused the tachypnea commonly suffered byanimals with advanced tumors.
Lung lymphatic vessels were sometimes strikingly distended bya glut of lympho-
blasts, and major blood vessels commonly contained large numbers, indicative of
lymphoblastic leukemia (see below). In some cases the pleura contained discrete
masses of lymphoblasts (Fig. 3E).
Muscle and bowel were sometimes involved. Cardiac muscle was occasionally
penetrated (Fig. 3 G), while intercostal muscle was extensively infiltrated by the
lymphoblasts accumulated along the thoracic vertebral column (Fig. 3H). How-
ever, neither these swellings nor the tumor deposits under the roof of the skull
(Fig. 31) ever reflected any infiltration of the spinal cord or the brain. In the
digestive tract, apart from a single cecal lymphoma, lymphoblasts were prevalent
only in Peyer's patches. When gross enlargement occurred, there was intrusion
into the lumen (Fig. 3,J) and, in cases of intussusception, a lymphoblast-packed
Peyer's patch could often be seen at the head of an everted portion of bowel,
drawn by peristalsis into the adjacent bowel (Fig. 3K).
Transplantability. To verify that the masses of lymphoblasts seen in the
enlarged lymphoid tissues of E,u-myc mice were malignant, up to 106 cells fromHARRIS ET AL.
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TABLE III
Transplantability ofEI-myc Tumor Cells
* Tissues were taken from seventh generation Eit-mycmice with advanced lymphoma.
tBSJF1 recipients were examined at 3-5-dintervalsafter subcutaneous and intraperitoneal injection
of cellsin 0.2 ml balanced salt solution containing 5% FCS.
each of 22 primary tumor animals were transplanted into normal BSJF1 mice.
Only two failed to generate tumors in the recipients within the 3-mo observation
period, and one other yielded tumors in only a few recipients. From the
remaining 19 donors, 105
-106
cells initiated tumors in all recipients, tumors
being apparent after 10-35 d and terminal illness by 20-50 d. Transplantation
titrations, in which cells from four donors were reduced in 10-fold steps from
105 to 10' cellsper recipient, yielded tumors at all cell doses. Examples are shown
in Table III. Irrespective of dose, all tumors arose within 10-30 d.
Withafewexceptions, the gross pathology (Fig. 2, EandF) and histopathology
(not shown) in transplant recipients was similar to that in the primary tumor
animals. Depending on the donor, tumor growth at the site of subcutaneous
injection varied from undetectable to very large masses, but was almost always
accompanied by enlargement of the lymph nodes, the spleen, and the thoracic
tissue around the vertebral column, and by infiltration of the thymus, the bone
marrow, the liver, and the lungs. The blood was leukemic and granulocytotic.
Transplant recipients did not, however, develop subparietal tumors or intussus-
ception, and enlarged Peyer's patches were rare.
Selective homing patterns were not evident. For example, cells from primary
thymomas did not predominantly cause thymic enlargement in recipients, and
cells from two subparietal tumors did notproduce visible growth inside the skull.
On the other hand, one largeprimarysubparietal tumor that showed little spread
to other organs produced massive tumor growth only at the subcutaneous
injection site, presumably reflecting its heritable inability to metastasize.
Transplantation provides a sensitive test for the presence of malignant cells
before overt tumors. We examined 149 EA-myc mice, between 4 and 10 wk of
age, thatappeared free ofdisease. Dissection revealed that 23 (15%) hadenlarged
lymph nodes and/or an enlarged thymus. 79 of the others were tested for
malignant cells by transplanting 1-5 x 106 bone marrow cells from both femurs
and, from some of these donors, 5-20 x 106 spleen and mesenteric lymph node
Donor
animal Donortissue*
105
Dayst
tumor
per
104
until first sign of
growth at cell numbers
recipient of:
103 102 10'
F-527 Mesenteric lymph node 18 18 21 26 21
21 21 21 26 26
21 21 21 26 32
F-527 Femoral bone marrow 18 18 21 21 21
18 26 26 26 26
26 26 26 30 26
F-546 Mesenteric lymph node 10 13 13 17 17
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TABLE IV
Leukocytes ofLymphomatous and Prelymphomatous Etc-mycMice
andNontransgenic Littermates
Animals ofboth sexes aged 6-21 wk in the terminal tumor group and 5-11 wk in the other three groups were bled from the heart
or the retroorbital sinus.
* Diluted heparinized blood was treated with Zaponin (Coulter Electronics) and the lysed-cell nuclei were counted and sized using a
Coulter Counter and Channelizer (see Materials and Methods).
$ Giemsa-stained blood smears were scored for polymorphs as a percentage of200-400 nucleatedcells.
i Concentrations were calculated from each percentage and the corresponding Coulter count ofnuclei.
cells, by subcutaneous and intraperitoneal injection into normal BSJF1 mice.
Within 2 mo, eight had generated disseminated lymphomas in the recipients, all
of which were observed for at least 3 mo. Thus, overall, 24% of ostensibly
healthy transgenic animals were actually in early stages of lymphoma develop-
ment .
Blood Leukocytes.
￿
The lymphoblasts in sections of blood vessels from animals
with advanced lymphoma indicated that the disease had a leukemic component.
The development of leukemia was therefore investigated by microscopic exami-
nation of blood smears and by counting and sizing blood cell nuclei in a Coulter
Counter. Terminally ill animals and those at an early stage oftumor development
were compared with pretumor young adult E/-myc animals and their nontrans-
genic littermates.
Table IV shows that, although white-cell parameters varied greatlywithin each
group, there were clear differences between the four groups. On average,
pretumor animals had somewhat more cells and slightly larger nuclei than the
nontransgenic controls. The blood of most lymphomatous animals, however,
contained markedly more cells and larger cell nuclei (Table IV), and stained
smears revealed large lymphoid cells (Fig. 3L), even when the total leukocyte
count was within the normal range. Clearly, though, the extent to which these
lymphoblasts invaded the circulation varied greatly in both early and late stages
of tumor growth in different animals. Fig. 4 depicts examples of nuclear size
distributions from which the mean volumes were computed. The profiles from
lymphomatous animals (Fig. 4, c-J) were all distinguishable from those from
healthyanimals (Fig. 4, a and b), but appeared to vary in the relative proportions
of nuclei of two sizes, centered on ^-35 and ^-60 fl.
Leukemic blood frequently had more abundant granulocytes (Table IV and
Fig.3L). 10 of 13 advanced cases scored for these cells had levels higher than
Parameter Nontransgenic
Pretumor
Eg-myc
Early tumor Terminal tumor
Nucleated cells (x 106/ml)*
Range (number of samples) 1.5-8.1 (22) 2.3-11 (10) 3.0-41 (17) 3.7-130 (17)
Geometric mean i SD 4.2 + 1 .6 5.7 + 1 .7 11 + 2.3 29 + 4.0
Mean nuclear volume (fl)*
Range (number ofsamples) 35-39 (18) 37-41 (10) 40-57 (8) 41-70 (17)
Mean ± SD 37.4±1 .0 39.6±1.4 49.2±6.6 52.9±6.5
Polymorphs (Percent of nucleated cells)$
Range(number ofsamples) 6-17 (15) 5-20 (10) 4-34 (16) 5-45 (13)
Mean ± SD 11.4±3.3 10.1±5.2 14.2±7.4 19.5±15.2
Polymorphs (x 1 Os/ml)f
Range (number ofsamples) 2-8 (15) 2-14 (10) 5-49 (16) 4-180 (13)
Geometric mean + SD 4.2 i 1 .7 5.2 X 1.8 14 + 2.1 28 + 3.112
10
2
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FIGURE 5. Leukocyte nuclear size in weanling
Ep-myc mice and nontransgenic littermates. 10 lit-
ters (71 mice), born of normal females mated to
Eg-myc males, were tested for transgene carriage
by tail DNA hybridization and were bled for de-
termination of mean leukocyte nuclear volume at
21-27 d of age. Filled areas indicate transgene-
positive animals, open areas transgene-negative an-
imals. Nuclear volumes were measured on Za-
ponin-lysed blood from the retroorbital sinus with
a Coulter Counter and Channelizer.
the maximum in the 15 control animals tested . The granulocytosis presumably
is a response to tumor cells, since it developed also in BSJF1 animals carrying
transplanted lymphomas (not shown).
Rapid Identification ofEw-myc Mice.
￿
In producing large numbers oftransgenic
animals, it becomes very time-consuming to identify the transgenic progeny of
heterozygous parents by DNA hybridization. The slightly enlarged leukocyte
nuclei in young adult Eu-myc mice (Table IV), together with our earlier finding
that B-lymphoid cells in these animals cycle more than normal (14), led us to test
whether they could be identified at weaning (3 wk) by size measurements on
blood leukocyte nuclei. Fig. 5 compares the frequency distribution of mean
nuclear size with results of tail DNA hybridization tests on 21- to 27-d pups.
Fortunately, the nuclear size difference was accentuated at this age. Despite the
spread of values in the normal group (Fig. 5, open bars) and the apparent
bimodality in the transgene-positive group (Fig. 5, solid bars), >90% could be
confidently classified by this rapid test, which requires only 5 A1 of blood (see
Materials and Methods). Subsequent routine tests on several hundred weanlings
have confirmed that mean nuclear volumes above 43 fl are reliably diagnostic of
transgene carriage and below 42 fl of normality. Weanlings with values of 42 or
43 fl are either retested by DNA hybridization or discarded.
The concentration of leukocytes was also elevated in most weanling Eu-myc
mice. While 90% ofnormal weanlingshad from 4 to 10 X 106/ml, theirtransgenic
littermates had 8.5-50 X 106/ml with a median of 19 X 106/ml. Therefore, cell
counts identify most transgenic animals, but nuclear volume has proven more
a F1 AA e
FIGURE 4. Size distributions ofleu-
kocyte nuclei from normal and from
Eu-myc mice. The animals, the mean
volumes of their leukocyte nuclei,
and their leukocyte counts were; (a)
42-d nontransgenic, 37 fl, 8 .1 X
V 0 25 50 75 100 0 25 50 75 100 0 25 50 75 100 106/ml; (b) 42-d Ep-myc pretumor, 40
a
b d f fl, 11 X 106/ml; (c, d, e, andf) Ey-
myc mice with advanced lymphoma,
48, 59, 52, and 51 fl, 88, 43, 4.5, and
U
J~.
130 X 106/ml, respectively. Counts
and volumes were derived from Za-
ponin-lysed blood with a Coulter
I I . - I . I Counter and Channelizer.
0 25 50 75 100 0 25 50 75 100 0 25 50 75 100364
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discriminating . Comparison of the data from young adults (Table IV) and from
weanlings (Fig. 5) reveals that early in the life of an Eu-myc mouse there is a
transient flood of enlarged leukocytes into the circulation . These cells have
lymphoid morphology in stained smears (not shown) .
Immunologic Classification of Tumors.
￿
Since the tumors consisted of lympho-
blasts, they would be classified as lymphoblastic lymphomas, but tumors of this
morphology can derive from either the T or the B lineage (19) . Therefore, cells
from primary lymphomas were tested for staining with fluorescent antibodies
against the T cell marker Thy-I and the B-lineage markers Ly5(B220) and Ig .
None of 31 tumors tested bore Thy-1, not even the thymic cells from six animals
with dominant thymoma . 6 of the 31 showed surface expression of Ig on
essentially all cells, while another 9 contained mixed populations of tumor cells
ranging from 5% to 87% surface Ig' . Of 16 Thy-l- tumors tested for the Ly-
5(B220) surface antigen, 15 were positive . In addition, primary tumors and
cultured tumor cell lines all carry rearranged Ig genes (16; Cory, S., A. W.
Harris,W. Y. Langdon, andJ . M . Adams, manuscript in preparation) . Thus all
EA-myc tumors appear to derive from the B-lineage, pre-B lymphomas and mixed
pre-B/B lymphomas predominating .
Tumors in Nontransgenic Mice.
￿
Middle-aged SJL mice develop a tumor known
as reticulum cell neoplasm, type B (20) . Because the EA-myc animals contained a
variable assortment of genes of SJL (and of C57BL) origin, we assessed the
incidence and nature oftumors arising in a groupof>I00 of theirnontransgenic
littermates . No tumors were found until 10 mo, when one mouse was killed with
a disseminated lymphoma, and two others began to develop slowly progressing
tumors . 10 of the 105 animals surviving the first year were killed during the
following 6 mo with advanced tumors in lymphoid organs, and 21 others were
killed (sick, or with fight wounds) without evidence of neoplasia . When the 75
survivors were autopsied at 18 mo ofage, 25 had one or more enlarged lymphoid
organs . The estimated tumor incidence in the 12- to 18-mo age range was 37%
(35/95) .
The gross pathology varied, partly because a third of the tumorous animals
were killed while apparently healthy, but the most frequent findings were greatly
enlarged mesenteric lymph nodes (83%) and large spleens (69%) (Fig . 6A) . In
16 of the 36 tumor-bearing animals (44%), one or more Peyer's patches were
enlarged (Fig . 6A) . Widespread lymph node enlargement was found only in sick
animals and probably is a late event in tumor progression.
None of the 31 tumors from nontransgenic animals examined histologically
were lymphoblastic lymphomas. A few comprised fairly uniform masses of large
lymphoid cells with moderate amountsof faintly staining cytoplasm andprobably
were follicular center cell lymphomas . Most tumors, however, were highly varied
mixtures of lymphoid and nonlymphoid cells, like those described as reticulum
cell neoplasm, type B (21) . The mesenteric lymph node was replete with such
cells, often including distinctive giant multinucleate cells (Fig . 6B) . The large
nodular spleen (Fig . 6C) contained greatly enlarged white pulp areas filled with
tumor cells, and increased hematopoiesis in the red pulp . The lungs contained
discrete tumor nodules (Fig . 6C) .
This histologic picture held for only two of the 134 EA-myc animals, one ofHARRIS ET AL .
FIGURE 6 . Gross pathology and histopathology of tumors in nontransgenic BSJF1-back-
crossed mice . The animals commonly exhibited (A) enlarged mesenteric lymph node and
Peyer's patch(es) and an enlarged, nodular spleen (X 1 .9) ; (B) mesenteric lymph node contain-
ing an abnormal mixture of cells including a giant multinucleate cell (X 600) ; and (C) lung
containing dense nodular deposits of tumor cells (X 60) .
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which succumbed at 42 wk of age with both reticulum cell neoplasm, type B and
lymphoblastic lymphoma. The other, the longest surviving confirmed transgene
carrier, became ill at 83 wk of age with reticulum cell neoplasm, including
nodular lung deposits. This unfortunateanimal had won a Pyrrhic victory against
the high odds of developing a lymphoblastic lymphoma!
Discussion
We have characterized the E,y-myc mouse in some detail as a model for
lymphoid tumorigenesis. After a variable period during which there is a benign,
limited overgrowth of pre-B cells (14), essentially every mouse develops tumors.
Although the disease manifestations are somewhat variable in detail (Table II
and Fig. 2), the dominant picture is disseminated lymphoma. The morphology
of the tumor cells, and the almost invariant infiltration of the lungs and liver
(Fig. 3, D, E, and F) fit the classification of lymphoblastic lymphoma in the
Pattengale-Taylor (19) scheme for mouse lymphoid tumors.
Lymphoblastic lymphomas of mice can derive from either the T or the B
lineage (19). An enlarged thymus is usually indicative of a T lymphoma, such as
thosethat arise in AKR and C58 mice, or in other strainsgiven Moloney leukemia
virus or x rays (e.g., reference 22). Thymic enlargement was common in E'-myc
mice with advanced tumors (Table II), and in 9 of 134 it was the dominant
abnormality at autopsy. Nevertheless, all these proved to be B-lineage tumors,
mostly pre-B lymphomas. Since pre-B cells arenotfoundin theprelymphomatous
thymus (14), and since the lymphoma cells commonly metastasized to the thymus
after transplantation, we assume that the primary thymomas were caused by
invasion from outside the thymus. The same argument applies to the lymph
nodes and leads us to suggest that acquisition by pre-B cells of the ability to
invade the thymus and lymph nodes is a critical step in tumor development.
Some other B-lineage tumors are known to metastasize to the thymus to a limited
extent, including B-immunoblastic lymphomas (23) and the B-lymphocytic leu-
kemia line BCL, (24). The pre-B lymphoblastic lymphomas induced by Abelson
virus, on the other hand, never appear to involve the thymus (25, 26).
Features common to Abelson and Ea-myc tumors, apart from the enlarged
lymph nodes and spleen common to most mouse lymphomas, are the deposits
inside the skull and along the vertebral column. It has been postulated that these
prominent features of Abelson disease are formed by cells emerging from the
marrow of adjacent bones (26). With advanced EA-myc tumors, vertebral column
swelling by lymphoma cells was common ; tumors inside the skull much less so .
Recipients of transplanted cells did not develop skull tumours, but usually did
show paravertebral tumor and bone marrow invasion. Thus, pre-B lymphoma
cells can readily metastasize from the periphery to the tissues along the vertebral
column, although this could involve an intermediate sojourn in the regional bone
marrow.
The rate of appearance of tumors in EA-myc mice is not constant throughout
life (Fig. 1). In the first few weeks it averages -5% per week, later increasing to
17% per week and finally falling again to 6% per week. The low initial rate may
reflecta smaller number of cells at risk of malignant transformation in the young
growing animal . It is also possible that the differing rates manifest the presenceHARRIS ET AL.
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of genetically determined subpopulations of animals, since the genetic back-
ground is a segregating mixture ofC57BL and SJL alleles. From ^"6 wk of age,
when adult size is neared, the tumor onset rate is constant at 17% per week for
^-70% ofthe animals. This corresponds to a mean time of 38 d for a malignancy-
initiating event in mice of 6-16 wk of age. Animals remaining free oftumor for
longer periods appear to represent a relatively resistant subpopulation with an
onset rate of only 6% per week and a mean time of 108 d to initiation of
malignancy. This reduced rate is associated with a reduced expansion ofthe pre-
B cell population in the pretumorous animals (14), and appears to be genetically
determined. Preliminary results from serial backcrossing with inbred C57BL/6J
mice indicate that one or more C57BL genes confer a relative resistance to
transgene-associated lymphomagenesis (Harris, A. W., unpublished observa-
tions).
Since early-onset tumors did not progress more rapidly than late-onset tumors
(Fig. 1), the early tumors are not simply the more aggressive ones. Instead, the
random onset must be related to the appearance ofthe first malignant cell within
each animal. That cell must be generated by a low-frequency event, presumably
a genetic accident, within the abnormally expanded pre-B population. We can
estimate the frequency ofmalignant conversion. The young adult EA.-myc mouse
contains -2.4 X 108 pre-B cells, most of which are in a proliferative state (14).
If half these cells divide on average every 8 h, like the cycling subset of pre-B
cells in a normal mouse (27), then in the 38 d required for each tumor-initiating
event to occur, the total pre-B pool will have undergone about 101° cell divisions.
Thus, the rate of occurrence of malignancy-inducing events is about 10-1° per
cell per generation . This is an exceptionally low rate for a single mutation.
Perhaps only certain extremely specific mutations suffice, or perhaps even a
dysregulated myc gene-expressing pre-B cell requires two mutations to become
a malignant cell. Another possibility is that most newly mutated potentially
malignant cells are eliminated by the mechanisms responsible for the rapid
turnover of pre-B cells before their mutant phenotype can be effectively ex-
pressed.
The high transplantability ofthe primary lymphomas (Table III) implied that
transplantation might reveal malignant cells in transgenic animals not yet exhib-
iting signs oflymphoma. When many such animals were examined internally for
lymphoid organ enlargement and tested for transplantable tumor cells, 24%
proved to be in early stages of lymphoma development. By relating this figure
to the tumor onset rate of 17% per week, we conclude that lymphomas actually
initiate in EIA-myc mice an average of 10 d before externally recognizable signs
become apparent.
We found that the EA-myc mice develop leukemia as well as lymphoma.
Although other mouse lymphoid malignancies are commonly called leukemias,
it is difficult to find published quantitative data on the blood cells, and qualitative
statements (e.g., references 19, 25, 26, 28) suggest that those tumor models do
not develop the high concentrations ofcirculating tumor cells that can occur in
human leukemias. An exception is the mouse chronic B-lymphocytic leukemia
BCL1, which yields blood concentrations 10-30 times above normal leukocyte
levels (24). Abelson pre-B lymphomas are associated with a granulocytosis, but368
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no detectable lymphoid leukemia (25, 26). Lymphomatous EA-myc animals, on
the other hand, commonly show both a myelocytic leukemoid reaction and a
substantial lymphoblastic leukemia. The granulocytosis might be provoked by
factors released from the lymphoma cells.
Because there are many more largepre-B and B cells than normal in the spleen
and bone marrow of the prelymphomatous EA-myc mouse (14), it seemed likely
that the B cells in the blood would also be larger. The average size of total
leukocyte nuclei in young adult transgenic animals did tend to be higher than
normal (Table IV and Fig. 4), but larger differences were seen with younger
animals, most weanling transgenic and nontransgenic animals falling into two
distinct groups (Fig. 5). We have subsequently used this rapid test to identify
transgenic progeny in the Eu-myc line, with an error rate of G5% in several
hundred mice. The apparent bimodal distribution of mean nuclear volumes
among the transgenic weanlings (Fig. 5) may reflect their genetic heterogeneity
and is under investigation. The blood cell assays revealed that, early in life,
elevated numbers of enlarged lymphoid (presumably B or pre-B) cells circulate
in the blood of the Ey-myc mouse. This phenomenon is present at 21 d through
33 d of age, but has almost disappeared by 42 d (Fig. 4). In a few animals, of
course, the early leukocytosis reflects early-onset leukemia, but in the majority,
whose tumors initiate later, there is an intervening period in which the size and
number of blood white cells are near normal.
All EA-myc tumors seem to derive from the B-lymphoid lineage, but they are
not all uniform in phenotype; we found pre-B lymphomas, mixed pre-B and B
lymphomas, and B lymphomas. The random initiation and the demonstrated
clonality of EI-myc tumors (16) indicate that the mixed tumors, and perhaps even
the "pure" B lymphomas, are descendants of malignant pre-B cells that can
differentiate. In this respect, they differ from Abelson tumors that rarely make
the step from pre-B cell to surface Ig-expressing B cell (29, 30). We have seen
no evidence of spontaneous plasmacytoma, the third main class of B-lineage
tumor, by electrophoretic screeningofmany EIA-myc sera for paraproteins (Harris,
A. W. and M. Crawford, unpublished observations).
We looked for possible relationships with the tumors that arise in some
nontransgenic littermate animals possessing the same mixture of C57BL and SJL
genes. None of more than 100 nontransgenic animals developed tumors within
the first 9 mo of life, a period that saw 98% of the Eli-myc group succumb; but
when monitoring was concluded at 18 mo, the incidence was 37%. The tumors,
which enlarged some lymphoid organs, varied histologically from uniformlylarge
lymphoid cells, through mixed collections of lymphoid and nonlymphoid cells,
to sarcoma-like masses of fusiform cells. They were all readily distinguishable
from the lymphoblastic lymphomas in the transgenic animals. Also, the lung
infiltration was nodular rather than diffuse. Thus, the E,u-myc transgene did not
simply hasten the onset of the tumors that would have occurred later in its
absence.
The tumors in the nontransgenic animals resembled those characteristic of
middle-aged SJL mice. SJL tumors vary in cell composition, and their classifica-
tion, nature, and malignant character is uncertain (19, 21, 31-33). Some are
said to contain neoplastic pre-B cells (31) and many are associated with clonalHARRIS ET AL.
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proliferations of Ig-secreting cells (34). Therefore, despite the morphological
differences between SJL and EI-myc tumors, SJL genes (such as Rcs-1 [35]) that
predispose to the so-called reticulum cell neoplasm may accelerate lymphoma-
genesis in Etu-myc animals. Our preliminary results with C57BL-backcross animals
support this idea and suggest that the EA-myc strain might be useful in exploring
other inbred mouse strains for genes which can modulate B-lymphoid tumori-
genesis.
Because the initiation of malignancy occurs at random in EI-myc mice, we
believe these mice constitute a model of spontaneous onset lymphoma and
leukemia. In its high incidence early in life, rapid progression, mixed lymphoma-
leukemia pathology and predominantly pre-B cell origin, the disease can be
considered as a murine analog of the common form of childhood acute lym-
phoblastic leukemia (36-38).; The nature of the low-frequency events, possibly
spontaneous mutations in other oncogenes, that generate the first neoplastic
lymphoid cell is under study. Such animals should provide a highly sensitive assay
for carcinogens. Moreover, by introducing other known oncogenes into these
animals, or into their pre-B cells in vitro, it should be feasible to delineate which
of them can cooperate with a dysregulated myc gene to precipitate B-lymphoid
malignancy.
Summary
Mice transgenic for a c-myc gene driven by the IgH enhancer (EA-myc) were
shown to almost invariably develop lymphomas, 90% succumbing in the first 5
mo of life. The tumors typically presented as rapidly progressive lymphadenop-
athy with thymic involvement and were highly malignant by transplantation
assay. Morphologically, they were lymphoblastic lymphomas, usually accom-
panied by lymphoid leukemia and granulocytosis, and were distinct from the
tumors that arose much later in 37% of nontransgenic mice ofthe same (C57BL/6
X SJL)F2 genetic background. Cell-surface markers on 31 Ett-myc tumors identi-
fied 52% as pre-B lymphomas, 29% as mixed pre-B and B lymphomas, and 19%
as B lymphomas. The tumors appeared to arise at random from a population of
pre-B cells expanded by constitutive expression of the myc transgene. A majority
of the animals initiated malignancy at the rate of 17% per week. The rate at
which the cycling, benign pre-B cells spontaneously convert to malignancy was
estimated to about 10- ' ° per cell per generation.
A transient leukocytosis identified in young Eu-myc mice was developed into a
rapid assay for inheritance of the transgene.
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